HER2 in prostate cancer - A viable target or innocent bystander? Journal Article


Author: Scher, H. I.
Article Title: HER2 in prostate cancer - A viable target or innocent bystander?
Keywords: immunohistochemistry; controlled study; protein expression; treatment outcome; unclassified drug; oncoprotein; androgen; pathogenesis; treatment planning; antineoplastic agents; drug targeting; ki 67 antigen; cell proliferation; ki-67 antigen; biological marker; prostate specific antigen; animals; in situ hybridization, fluorescence; gene overexpression; breast cancer; diagnosis, differential; epidermal growth factor receptor; epidermal growth factor receptor 2; cohort analysis; gene product; editorial; cytotoxicity; food and drug administration; protein tyrosine kinase; drug specificity; prostate cancer; prostate-specific antigen; prostatic neoplasms; health care cost; rna; gene expression regulation, neoplastic; basal cell; antibodies, monoclonal; fluorescence in situ hybridization; dna; disease progression; ligand; predictive value of tests; androgen receptor; receptor, erbb-2; orchiectomy; diagnostic test; up-regulation; tumor growth; molecular biology; trastuzumab; genes, erbb-2; cytological techniques; protein antibody; guanine nucleotide exchange factors; oncogene neu; cancer antibody; target organ; humans; human; male; priority journal
Journal Title: JNCI: Journal of the National Cancer Institute
Volume: 92
Issue: 23
ISSN: 0027-8874
Publisher: Oxford University Press  
Date Published: 2000-12-06
Start Page: 1866
End Page: 1868
Language: English
PUBMED: 11106669
PROVIDER: scopus
DOI: 10.1093/jnci/92.23.1866
DOI/URL:
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Howard Scher
    841 Scher